Maxim Group analyst Michael Okunewitch initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and announces Price Target of $24.
Related Posts
How Is The Market Feeling About Stryker?
Stryker’s (NYSE:SYK) short percent of float has risen 14.29% since its last report. The company recently reported that it has…
Wedbush Reiterates Neutral on Logitech International, Maintains $80 Price Target
Wedbush analyst Alicia Reese reiterates Logitech International (NASDAQ:LOGI) with a Neutral and maintains $80 price target.
JP Morgan Maintains Neutral on Lockheed Martin, Lowers Price Target to $481
JP Morgan analyst Seth Seifman maintains Lockheed Martin (NYSE:LMT) with a Neutral and lowers the price target from $495 to…